Targeted development of specific biomarkers of endometrial stromal cell differentiation using bioinformatics: The IFITM1 model

Modern Pathology

Volumn 27, Issue 4, 2014, Pages 569-579

  Parra Herran, Carlos E ^a   Yuan, Liping ^a   Nucci, Marisa R ^a   Quade, Bradley J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

endometrial stroma; endometrial stromal neoplasms; IFITM1

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; INTERFERON INDUCED TRANSMEMBRANE PROTEIN 1; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; DIFFERENTIATION ANTIGEN; LEU-13 ANTIGEN; TUMOR MARKER;

ADENOMYOSIS; ARTICLE; BIOINFORMATICS; CANCER GRADING; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENDOMETRIAL STROMAL TUMOR; ENDOMETRIUM SARCOMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; MUSCLE TUMOR; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERUS SARCOMA; UTERUS TUMOR; BIOLOGY; CHEMISTRY; ENDOMETRIUM TUMOR; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROTEIN DATABASE; STROMA CELL;

ANTIGENS, DIFFERENTIATION; CELL DIFFERENTIATION; COMPUTATIONAL BIOLOGY; DATABASES, PROTEIN; ENDOMETRIAL NEOPLASMS; ENDOMETRIAL STROMAL TUMORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 84897507036     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.123     Document Type: Article

References (34)

1. Nucci MR, O'Connell JT, Huettner PC, et al. H-caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors. Am J Surg Pathol 2001;25:455-463.
2. Rush DS, Tan J, Baergen RN, et al. H-caldesmon, a novel smooth muscle-specific antibody, distinguishes between cellular leiomyoma and endometrial stromal sarcoma. Am J Surg Pathol 2001;25:253-258.
3. Chu PG, Arber DA, Weiss LM, et al. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Mod Pathol 2001;14: 465-471.
4. McCluggage WG, Sumathi VP, Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and endometrial stromal neoplasms. Histopathology 2001; 39:273-278.
5. Toki T, Shimizu M, Takagi Y, et al. CD10 is a marker for normal and neoplastic endometrial stromal cells. Int J Gynecol Pathol 2001;21:41-47.
6. Abeler VM, Nenodovic M. Diagnostic immunohistochemistry in uterine sarcomas: a study of 397 cases. Int J Gynecol Pathol 2011;30:236-243.
7. Oliva E, Young R, Amin M, et al. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus. Am J Surg Pathol 2002;26:403-412.
8. D'Angelo E, Spagnoli LG, Prat J. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system. Hum Pathol 2009;40:1571-1585.
9. Zhu XQ, Shi YF, Cheng XD, et al. Immunohistochemical markers in differential diagnosis of endometrial stromal sarcoma and cellular leiomyoma. Gynecol Oncol 2004;92:71-79.
10. Koivisto-Korander R, Butzow R, Koivisto AM, et al. Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma: expression and prognostic importance of ten different markers. Tumor Biol 2011;32:451-459.
11. Lee CH, Ali RH, Rouzbahman M, et al. Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Am J Surg Pathol 2012;36:1562-1570.
12. Park HJ, Kuk IS, Kim JH, et al. Characterization of mouse Interferon-induced transmembrane protein-1 gene expression in the mouse uterus during oestrus cycle and pregnancy. Reprod Fertil Dev 2011;23:798-808.
13. Lewin AR, Reid LF, McMahon M, et al. Molecular analysis of a human interferon-inducible gene family. Eur J Biochem 1991;199:417-423.
14. Reid LE, Brasnett AH, Gilbert CS, et al. A single DNA response element can confer inducibility by both a and g-interferons. Proc Natl Acad Sci 1989;86:840-844.
15. Huang IC, Bailey CC, Weyer JL, et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS, coronavirus and influenza A virus. PLoS Pathogens 2011;7:1-13.
16. Friedman RL, Manly SP, McMahon M, et al. Transcriptional and posttranscriptional regulation of Interferoninduced expression in human cells. Cell 1984;38: 745-755.
17. Yang G, Xu Y, Chen X, et al. IFITM1 plays an essential role in the antiproliferative action of interferon-g. Oncogene 2007;26:584-603.
18. Lu J, Pan Q, Rong L, et al. The IFITM1 proteins inhibit HIV-1 infection. J Virol 2011;85:2126-2137.
19. Brass AL, Huang IC, Benita Y, et al. IFITM proteins mediate the innate immune response to influenza A H1N1 virus, West Nile virus and Dengue virus. Cell 2009;139:1243-1254.
20. Hou X, Tan Y, Li M, et al. Canonical Wnt signaling is critical to estrogen-mediated uterine growth. Mol Endocrinol 2004;18:3035-3049.
21. Xie H, Tranguch S, Jia X, et al. Inactivation of nuclear Wnt-b catenin signaling limits blastocyst competency for implantation. Development 2008;135:717-727.
22. Tanaka SS, Yamaguchi YL, Lickert H, et al. IFITM/mil/fragilis family proteins IFITM1 and IFITM3 play distinct roles in mouse primordial germ cell moning and repulsion. Dev Cell 2005;9:745-756.
23. Li J, Roebuck P, Grunewald S, et al. SurvNet: a web server for identifying network-based biomarkers that most correlate with patient survival data. Nucleic Acids Res 2012;40:W123-W126.
24. Fagerberg L, Strömberg S, El-Obeid A, et al. Large-scale protein profiling in human cell lines using antibodybased proteomics. J Proteome Res 2011;10:4066-4075.
25. Pontén F, Schwenk JM, Asplund A. The Human Protein Atlas as a proteomic resource for biomarker discovery. J Intern Med 2011;270:428-446.
26. Uhlén M, Björling E, Agaton C, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 2005;4:1920-1932.
27. Haggarth L, Hagglof C, Jaraj SJ, et al. Diagnostic biomarkers of prostate cancer. Scand J Urol Nephrol 2011;45:60-67.
28. Magnusson K, de Wit M, Brennan DJ, et al. SATB2 in combination with cytokeratin 20 identified over 95% of all colorectal carcinoma. Am J Surg Pathol 2011;35:937-948.
29. Ehlen A, Nodin B, Rexhepaj E, et al. RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer. Transl Oncol 2011;4:212-221.
30. Edlund K, Lindskog C, Saito A, et al. CD99 is a novel prognostic stromal marker in non-small cell lung cancer. Int J Cancer 2012;131:2264-2273.
31. Lindskog C, Korsgren O, Ponten F, et al. Novel pancreatic beta cell-specific proteins: antibody-based proteomics for identification of new biomarker candidates. J Proteomics 2012;75:2611-2620.
32. Davidson B, Abeler VM, Hellesylt E, et al. Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma. Gynecol Oncol 2013;128:349-355.
33. Pontén F, Jirström K, Uhlen M. The Human Protein Atlas-a tool for pathology. J Pathol 2008;216:387-393.
34. Asplund A, Edqvist PH, Schwenk JM, et al. Antibodies for profiling the human proteome-The Human Protein Atlas as a resource for cancer research. Proteomics 2012;12:2067-2077.